Newborn Screening: Key Industry Insights, Current and Future Perspectives

What This Report Will Provide?

This study involved four major activities in estimating the current size of the newborn screening market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth:

[177 Pages Report]
 The newborn screening market size is projected to reach USD 1.3 billion by 2026 from USD 0.9 billion in 2021, at a CAGR of 8.3%

Major Growth Boosters:

Growth in this market is majorly driven by the increasing prevalence of newborn disorders, favourable reimbursement polcies. However, the availability of refurbished products are expected to restrain the growth of this market to certain extent during the forecast period.

Download PDF Brochure:

Recent Developments:

In September 2020,  PerkinElmer (US) recevied CE-IVD approval for EONIS screening assay used to screen SMA (spinal muscular atrophy), SCID (severe combined immunodeficiency), and XLA (X-linked agammaglobulinemia) in newborns

In December 2019, PerkinElmer (US) received US FDA approval for GSP Neonatal Creatine Kinase –MM (CK-MM) kit for screening newborns affected by Duchenne muscular dystrophy (DMD)

In October 2019, Demant A/S (Denmark) has lancuehd its easyScreen BERAphone, a hearing screening device, at the 64th International Congress of Hearing Aid Acousticians in Nuremberg, Germany

In January 2018, Demant A/S (Denmark) has launched GSI Novus, a handheld newborn hearing screener

Regional Growth Analysis:

The newborn screening market, by region, has been segmented into North America, Europe, the Asia Pacific, and the Rest of the world (RoW). North America is the largest market for newborn screening, followed by Europe. Growth in the North American market can be attributed to the availability of newborn screening programs, favorable reimbursement policies, and a strong market player presence.

The Asia Pacific is expected to register the highest CAGR during the forecast period. Growth in this region is driven by the large newborn pool, increasing screening rate, and rising awareness regarding early diagnosis. India, China, and Brazil provide significant opportunities to players in this market due to their high birth rates and increasing disposable income.

Key Questions Addressed in The Report:

1. Who are the top 10 players operating in the newborn screening market?
2. What are the drivers, restraints, opportunities, and challenges in the newborn screening Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of newborn screening in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?

Request Sample Report:

Key Players:

Prominent players in the newborn screening market are PerkinElmer (US), Natus Medical (US), Bio-Rad Laboratories (US), Danaher Corporation (US), and Medtronic (Ireland). Others include Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies (US), Parseq Lab (Russia), Recipe Chemicals+Instruments (Germany), and Demant A/S (Denmark).